2021/04/11
MVC Announced EV71 Vaccine MRCT Phase 3 Clinical Trial Immunogenicity Results
2021/04/07
MVC Announces Pre-Print Publication in MedRxiv Showing the Interim Analysis Result of First-in-Human Trial of a Recombinant SARS-CoV-2 Spike Protein (S-2P) Vaccine with Adjuvant of Aluminum Hydroxide and CpG 1018
2021/03/23
MVC Announces Pre-Print Publication in MedRxiv Evaluating the neutralizing ability of a CpG-adjuvanted S-2P subunit vaccine against SARS-CoV-2 Variants of Concern
2021/01/25
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
2020/12/30
MVC Obtained TFDA Phase 2 IND Approval for COVID19 Vaccine
2020/11/19
MVC Announces Publication in Scientific Reports of Positive Results From Preclinical Studies of Its Vaccine Candidate Against COVID-19
We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.
Agree